For genetic research to contribute more fully to furthering our knowledge of neuropathic pain we require an agreed, valid and feasible approach to phenotyping, in order to allow collaboration and replication in samples of sufficient size. Results from genetic studies on neuropathic pain have been inconsistent and have met with replication difficulties, in part because of differences in phenotypes used for case ascertainment. Since there is no consensus on the nature of these phenotypes, nor the methods of collecting them, this study aimed to provide guidelines on collecting and reporting phenotypes in cases and controls for genetic studies. Consensus was achieved through a staged approach: (1) systematic literature review to identify all neuropathic pain phenotypes used in previous genetic studies; (2) Delphi survey to identify the most useful neuropathic pain phenotypes, their validity and feasibility; and (3) meeting of experts to reach consensus on the optimal phenotype(s) to be collected from neuropathic pain patients for genetic studies. A basic ‘entry-level’ set of phenotypes was identified for any genetic study of neuropathic pain. This set identifies cases of ‘possible’ neuropathic pain, and controls, and includes: (1) a validated symptom-based questionnaire to determine whether any pain is likely to be neuropathic; (2) body chart or checklist to identify whether the area of pain distribution is neuroanatomically logical; and (3) details of pain history (intensity, duration, any formal diagnosis). This NeuroPPIC ‘entry-level’ set of phenotypes can be expanded by more extensive and specific measures, as determined by scientific requirements and resource availability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.